Literature DB >> 16061050

Antihypertensive treatment and new-onset diabetes mellitus.

Tonje Amb Aksnes1, Henrik M Reims, Sverre E Kjeldsen, Giuseppe Mancia.   

Abstract

The various antihypertensive regimens have varying effects on glucose metabolism and the development of diabetes mellitus. Recent large hypertension trials have shown great differences in the development of new-onset diabetes among antihypertensive drug therapies. The incidence of diabetes is unchanged or increased by thiazide diuretics and b-adrenergic blockers, and unchanged or decreased by angiotensin-converting enzyme inhibitors, calcium channel blockers, and angiotensin-receptor blockers. The differences in new-onset diabetes mellitus have not influenced the outcome of cardiovascular mortality and morbidity in all of the large clinical trials, but drug-induced diabetes among hypertensive patients is known to carry the same cardiovascular risk as that seen in patients with previously known diabetes; however, it might take years for the increased risk to become apparent.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061050     DOI: 10.1007/s11906-005-0029-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  44 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 2.  Diabetes mellitus. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1985

3.  Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle.

Authors:  S Jacob; E J Henriksen; D L Fogt; G J Dietze
Journal:  Metabolism       Date:  1996-05       Impact factor: 8.694

4.  The epidemiology of impaired glucose tolerance and hypertension.

Authors:  W B Kannel; P W Wilson; T J Zhang
Journal:  Am Heart J       Date:  1991-04       Impact factor: 4.749

5.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.

Authors:  Hans Lithell; Lennart Hansson; Ingmar Skoog; Dag Elmfeldt; Albert Hofman; Bertil Olofsson; Peter Trenkwalder; Alberto Zanchetti
Journal:  J Hypertens       Date:  2003-05       Impact factor: 4.844

Review 6.  Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition.

Authors:  E Ferrannini; G Seghieri; E Muscelli
Journal:  J Cardiovasc Pharmacol       Date:  1994       Impact factor: 3.105

7.  Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase.

Authors:  Panteleimon A Sarafidis; Anastasios N Lasaridis; Peter M Nilsson; Emmanuil M Pagkalos; Areti D Hitoglou-Makedou; Christodoulos I Pliakos; Kiriakos A Kazakos; John G Yovos; Pantelis E Zebekakis; Ioannis M Tziolas; Achilleas N Tourkantonis
Journal:  J Hypertens       Date:  2004-09       Impact factor: 4.844

8.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

9.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

10.  The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM.

Authors:  A Shamiss; J Carroll; E Peleg; E Grossman; T Rosenthal
Journal:  Am J Hypertens       Date:  1995-03       Impact factor: 2.689

View more
  4 in total

Review 1.  Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide?

Authors:  Thor Tejada; Alessia Fornoni; Oliver Lenz; Barry J Materson
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

2.  Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study.

Authors:  Elijah Saunders; Greg Cable; Joel Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-01       Impact factor: 3.738

3.  Treatment of hypertension among African Americans: the Jackson Heart Study.

Authors:  Jane Harman; Evelyn R Walker; Vicki Charbonneau; Ermeg L Akylbekova; Cheryl Nelson; Sharon B Wyatt
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-01       Impact factor: 3.738

4.  The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study.

Authors:  Olivia Currie; Dee Mangin; Jonathan Williman; Bianca McKinnon-Gee; Paul Bridgford
Journal:  BMJ Open       Date:  2013-11-21       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.